That biotech unicorn you (pick love or hate) just spotlighted some intriguing mouse (yes) data on a triple mRNA cancer therapy
The cancer team working under Moderna’s Tal Zaks have been tinkering with various combinations of mRNA in mice to see how best they can use this technology to orchestrate an immune system attack. And today they’re highlighting a preclinical rodent study that indicates they could be on a promising path that’s taken them into human trials.
Basic subscription required
Unlock this story instantly and join 55,100+ biopharma pros reading Endpoints daily — and it's free.